References
- R. Pahwa, A. Goyal, and I. Jialal, Chronic Inflammation, StatPearls Publishing, Treasure Island (FL), 2022. ( [Updated 2021 Sep 28]. In: StatPearls [Internet]).
- M.G. Netea, J. Domínguez-Andrés, L.B. Barreiro, T. Chavakis, M. Divangahi, E. Fuchs, L.A.B. Joosten, J.W.M. van der Meer, M.M.M. Hlanga, and W.J.M. Mulder, Defining trained immunity and its role in health and disease, Nat. Rev. Immunol. 20 (2020), pp. 375–388. doi:https://doi.org/10.1038/s41577-020-0285-6.
- M. Raihan, B. Espelien, B. McGregor, C. Hanson, A. Brishti, N. Velaris, T. Alvine, D. Bradley, M. Nilles, and M. Golovko, Modulation of inflammatory signaling molecules in Bordetella pertussis antigen-challenged human monocytes in presence of adrenergic agonists, Vaccines 10 (2022), pp. 321–334. doi:https://doi.org/10.3390/vaccines10020321.
- R.K. Chakraborty and B. Burns, Systemic Inflammatory Response Syndrome, StatPearls; StatPearls Publishing Copyright © LLC, Treasure Island (FL), 2022.
- C. Chu, D. Artis, and I.M. Chiu, Neuro-immune interactions in the tissues, Immunity 52 (2020), pp. 464–474. doi:https://doi.org/10.1016/j.immuni.2020.02.017.
- M.A. Sugimoto, L.P. Sousa, V. Pinho, M. Perretti, and M.M. Teixeira, Resolution of inflammation: What controls its onset? Front. Immunol. 7 (2016), pp. 00160.
- S. Hannoodee and D.N. Nasuruddin, Acute Inflammatory Response, StatPearls; StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC, Treasure Island (FL), 2022.
- L.A. Abdulkhaleq, M.A. Assi, R. Abdullah, M. Zamri-Saad, Y.H. Taufiq-Yap, and M.N.M. Hezmee, The crucial roles of inflammatory mediators in inflammation: A review, Vet. World 11 (2018), pp. 627–635. doi:https://doi.org/10.14202/vetworld.2018.627-635.
- M.M. Wolfe, D.R. Lichtenstein, and G. Singh, Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs, N. Engl. J. Med. 340 (1999), pp. 1888–1899. doi:https://doi.org/10.1056/NEJM199906173402407.
- R.S. Bresalie, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, and A. Lanas, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N. Engl. J. Med. 352 (2005), pp. 1092–1102. doi:https://doi.org/10.1056/NEJMoa050493.
- A. Whelton and C.W. Hamilton, Nonsteroidal anti‐ inflammatory drugs: Effects on kidney function, J. Clin. Pharmacol. 31 (1991), pp. 588–598. doi:https://doi.org/10.1002/j.1552-4604.1991.tb03743.x.
- E. Ricciotti and G.A. FitzGerald, Prostaglandins and Inflammation, Arterioscler. Thromb. Vasc. Biol. 31 (2011), pp. 986–1000. doi:https://doi.org/10.1161/ATVBAHA.110.207449.
- N. Zidar, K. Dimnik, D. Glavac, M. Jerse, T. Zupanc, and D. Stajer, Cyclooxygenase in normal human tissues–is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J. Cell. Mol. Med. 13 (2009), pp. 3753–3763. doi:https://doi.org/10.1111/j.1582-4934.2008.00430.x.
- T.S.R. Jensen, B. Mahmood, M.B. Damm, M.B. Backe, M.S. Dahllöf, S.S. Poulsen, M.B. Hansen, and N. Bindslev, Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients, BMC Gastroenterol. 18 (2018), pp. 31–47. doi:https://doi.org/10.1186/s12876-018-0759-1.
- J.-M. Dogné, C.T. Supuran, and D. Pratico, Adverse cardiovascular effects of the coxibs, J. Med. Chem. 48 (2005), pp. 2251–2257. doi:https://doi.org/10.1021/jm0402059.
- J.Z. Haeggström, Leukotriene biosynthetic enzymes as therapeutic targets, J. Clin. Invest. 128 (2018), pp. 2680–2690. doi:https://doi.org/10.1172/JCI97945.
- C. Hu and S. Ma, Recent development of lipoxygenase inhibitors as anti-inflammatory agents, Med. Chem. Commun. 9 (2018), pp. 212–225. doi:https://doi.org/10.1039/C7MD00390K.
- R. Morphy and Z. Rankovic, Medicinal Chemistry Approaches for Multitarget Drugs. Burger’s Med. Chem. Drug Discov, John Willet & Sons, Inc. H, oboken, 2003, pp. 249–274.
- M. Haroun, In silico design, synthesis and evaluation of novel series of benzothiazole-based pyrazolidinediones as potent hypoglycemic agents, Med. Chem. 16 (2020), pp. 812–825. doi:https://doi.org/10.2174/1573406416666191227113716.
- M. Haroun, Novel hybrids of pyrazolidinedione and benzothiazole as TZD analogues. Rationale design, synthesis and in vivo anti-diabetic evaluation, Med. Chem. 15 (2019), pp. 624–633. doi:https://doi.org/10.2174/1573406415666190515093657.
- Z.A. Muhammad, G.S. Masaret, M.M. Amin, M.A. Abdallah, and T.A. Farghaly, Anti-inflammatory, analgesic and anti-ulcerogenic activities of novel bis-thiadiazoles, bis-thiazoles and bis-formazanes, Med. Chem. 13 (2017), pp. 226–238. doi:https://doi.org/10.2174/1573406412666160920091146.
- D.I. Ugwu, U.C. Okoro, P.O. Ukoha, A. Gupta, and S.N. Okafor, Novel anti-inflammatory and analgesic agents: Synthesis, molecular docking and in vivo studies, J. Enz. Inhib. Med. Chem. 33 (2018), pp. 405–415. doi:https://doi.org/10.1080/14756366.2018.1426573.
- V. Kamat, R. Santosh, B. Poojary, S.P. Nayak, B.K. Kumar, M. Sankaranarayanan, Faheem, S. Khanapure, D.A. Barretto, and S.K. Vootla, Pyridine- and thiazole-based hydrazides with promising anti-inflammatory and antimicrobial activities along with their in silico studies, ACS Omega 5 (2020), pp. 25228–25239. doi:https://doi.org/10.1021/acsomega.0c03386.
- X.J. Zheng, C.S. Li, M.Y. Cui, Z.W. Song, X.Q. Bai, C.W. Liang, H.Y. Wang, and T.Y. Zhang, Synthesis, biological evaluation of benzothiazole derivatives bearing a 1,3,4-oxadiazole moiety as potential anti-oxidant and anti-inflammatory agents, Bioorg. Med. Chem. Lett. 30 (2020), pp. 127237–127244. doi:https://doi.org/10.1016/j.bmcl.2020.127237.
- E.N. Djuidje, R. Barbari, A. Baldisserotto, E. Durini, S. Sciabica, J. Balzarini, S. Liekens, S. Vertuani, and S. Manfredini, Benzothiazole Derivatives as multifunctional antioxidant agents for skin damage: Structure-activity relationship of a scaffold bearing a five-membered ring system, Antioxidants (Basel) 11 (2022), pp. 407–423. doi:https://doi.org/10.3390/antiox11020407.
- L.C. Cabrera-Pérez, I.I. Padilla-Martínez, A. Cruz, J.E. Mendieta-Wejebe, F. Tamay-Cach, and M.S. Rosales-Hernández, Evaluation of a new benzothiazole derivative with antioxidant activity in the initial phase of acetaminophen toxicity, Arab. J. Chem. 12 (2019), pp. 3871–3882. doi:https://doi.org/10.1016/j.arabjc.2016.02.004.
- K. Liaras, M. Fesatidou, and A. Geronikaki, Thiazoles and thiazolidinones as COX/LOX inhibitors, Molecules 23 (2018), pp. 685–706. doi:https://doi.org/10.3390/molecules23030685.
- S.D. Oniga, L. Pacureanu, C.I. Stoica, M.D. Palage, A. Crăciun, L.R. Rusu, E.L. Crisan, and C. Araniciu, COX inhibition profile and molecular docking studies of some 2-(trimethoxyphenyl)-thiazoles, Molecules 22 (2017), pp. 1507–1522. doi:https://doi.org/10.3390/molecules22091507.
- C. Tratrat, Novel thiazole-based thiazolidinones as potent anti-infective agents: In silico PASS and toxicity prediction, synthesis, biological evaluation and molecular modelling, Comb. Chem. High Throughput Screen. 23 (2020), pp. 126–140. doi:https://doi.org/10.2174/1386207323666200127115238.
- R. Kenchappa, Y.D. Bodke, S. Telkar, and S.M. Aruna, Antifungal and anthelmintic activity of novel benzofuran derivatives containing thiazolo benzimidazole nucleus: An in vitro evaluation, J. Chem. Biol. 10 (2016), pp. 11–23. doi:https://doi.org/10.1007/s12154-016-0160-x.
- S. Cascioferro, B. Parrino, and D. Carbone, Thiazoles, their benzofused systems, and thiazolidinone derivatives: Versatile and promising tools to combat antibiotic resistance, J. Med. Chem. 63 (2020), pp. 7923–7956. doi:https://doi.org/10.1021/acs.jmedchem.9b01245.
- A. Deep, B. Narasimhan, S.M. Lim, K. Ramasamy, and K.M. Kumar, 4-Thiazolidinone derivatives: Synthesis, antimicrobial, anticancer evaluation and QSAR studies, RCS Adv. 6 (2016), pp. 109485–109494.
- C. Tratrat, A. Petrou, A. Geronikaki, M. Ivanov, M. Kostic, M. Sokovic, I.S. Vizirianakis, N.F. Theodoroula, and M. Haroun, Thiazolidin-4-ones as potential antimicrobial agents: Experimental and in silico evaluation, Molecules 27 (2022), pp. 1930–1955. doi:https://doi.org/10.3390/molecules27061930.
- M. Haroun, C. Tratrat, A. Kolokotroni, A. Petrou, A. Geronikaki, M. Ivanov, M. Kostic, M. Sokovic, A. Carazo, P. Mladenka, N. Sreeharsha, K.N. Venugopala, A.B. Nair, and H.S. Elsewedy, 5-benzyliden-2-(5-methylthiazol-2-ylimino) thiazolidin-4-ones as antimicrobial agents. design, synthesis, biological evaluation and molecular docking studies, Antibiotics 10 (2021), pp. 309–328. doi:https://doi.org/10.3390/antibiotics10030309.
- M. Haroun, C. Tratrat, A. Petrou, A. Geronikaki, M. Ivanov, A. Ciric, M. Sokovic, N. Sreeharsha, K.N. Venugopala, A.B. Nair, H.S. Elsewedy, and H. Kochkar, Exploration of the antimicrobial effects of benzothiazolylthiazolidin-4-one and in silico mechanistic investigation, Molecules 26 (2021), pp. 4061–4086. doi:https://doi.org/10.3390/molecules26134061.
- Y. Ali, M.S. Alam, N. Hamid, A. Husain, A. Dhulap, S. Bano, and C. Kharbanda, Design, synthesis and biological screening of Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents, Bioorg. Med. Chem. Lett. 27 (2017), pp. 1017–1025. doi:https://doi.org/10.1016/j.bmcl.2016.12.069.
- S.B. Bari and S.D. Firake, Exploring anti-inflammatory potential of thiazolidinone derivatives of benzenesulfonamide via synthesis, molecular docking and biological evaluation, Antiinflamm. Antiallergy Agents Med. Chem. 15 (2016), pp. 44–53. doi:https://doi.org/10.2174/1871523015666160524141630.
- D.R.M. Moreira, D.S. Santos, R.F.D.E. Santo, F.E.D. Santos, G.B. de Oliveira Filho, A.C.L. Leite, M.B.P. Soares, and C.F. Villarreal, Structural improvement of new thiazolidinones compounds with antinociceptive activity in experimental chemotherapy-induced painful neuropathy, Chem. Biol. Drug Des. 90 (2017), pp. 297–307. doi:https://doi.org/10.1111/cbdd.12951.
- N. Agrawal, Synthetic and therapeutic potential of 4-thiazolidinone and its analogs, Curr. Chem. Lett. 10 (2021), pp. 119–138. doi:https://doi.org/10.5267/j.ccl.2020.11.002.
- R. Lesyk, Drug design: 4-thiazolidinones applications part 2, J. Med. Sci. 89 (2020), pp. 132–141.
- M. Djukic, M. Fesatidou, I. Xenikakis, A. Geronikaki, V. Angelova, V. Savic, M. Pasic, B. Krilovic, D. Djukic, B. Gobeljic, M. Pavlica, A. Djuric, I. Stanojevic, D. Vojvodic, and L. Saso, In vitro antioxidant activity of thiazolidinone derivatives of 1,3-thiazole and 1,3,4-thiadiazole, Chem. Biol. Interact. 286 (2018), pp. 119–131. doi:https://doi.org/10.1016/j.cbi.2018.03.013.
- S. Asghari, M. Pourshab, and M. Mohseni, Synthesis, characterization, and evaluation of antioxidant and antibacterial activities of novel indole-hydrazono thiazolidinones, Monatsh Chem. 149 (2018), pp. 2327–2336. doi:https://doi.org/10.1007/s00706-018-2292-x.
- A. Püre, M. Ergül, M. Ergül, A. Altun, and I. Küçükgüzel, Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids, Mol. Divers. 25 (2021), pp. 1025–1050. doi:https://doi.org/10.1007/s11030-020-10087-1.
- B. Skóra, A. Lewińska, A. Kryshchyshyn-Dylevych, D. Kaminskyy, R. Lesyk, and K.A. Szychowski, Evaluation of anticancer and antibacterial activity of four 4-thiazolidinone-based derivatives, Molecules 27 (2022), pp. 894–905. doi:https://doi.org/10.3390/molecules27030894.
- K. Szabó, R. Maccari, R. Ottanà, and G. Gyémánt, Extending the investigation of 4-thiazolidinone derivatives as potential multi-target ligands of enzymes involved in diabetes mellitus and its long-term complications: A study with pancreatic α-amylase, Carbohyd. Res. 449 (2021), pp. 108220. doi:https://doi.org/10.1016/j.carres.2020.108220.
- D. Subhedar, M. Shaikh, B. Shingate, L. Nawale, D. Sarkar, and V. Khedkar, Novel tetrazoloquinoline–thiazolidinone conjugates as possible antitubercular agents: Synthesis and molecular docking, Med. Chem. Commun. 7 (2016), pp. 1832–1848. doi:https://doi.org/10.1039/C6MD00278A.
- O. Güzel-Akdemir, S. Carradori, R. Grande, K. Demir-Yazıcı, A. Angeli, C.T. Supuran, and A. Akdemir, Development of thiazolidinones as fungal carbonic anhydrase inhibitors, Int. J. Mol. Sci. 21 (2020), pp. 2960–2977. doi:https://doi.org/10.3390/ijms21082960.
- M. Haroun, C. Tratrat, K. Kositzi, E. Tsolaki, A. Petrou, B. Aldhubiab, M. Attimarad, S. Harsha, A. Geronikaki, K. Venugopala, H. Elsewedy, M. Sokovic, J. Glamoclija, and A. Ciric, New benzothiazole-based thiazolidinones as potent antimicrobial agents. Design, synthesis and biological evaluation, Curr. Top. Med. Chem. 18 (2018), pp. 75–87. doi:https://doi.org/10.2174/1568026618666180206101814.
- A. Lagunin, A. Stepanchikova, D. Filimonov, and V. Poroikov, PASS: Prediction of activity spectra for biologically active substances, Bioinformatics 16 (2000), pp. 747–748. doi:https://doi.org/10.1093/bioinformatics/16.8.747.
- O. Kouatly, A. Geronikaki, C. Kamoutsis, D. Hadjipavlou-Litina, and P. Eleftheriou, Adamantane derivatives of thiazolyl-N-substituted amide, as possible non-steroidal anti-inflammatory agents, Eur. J. Med. Chem. 44 (2009), pp. 1198–1204. doi:https://doi.org/10.1016/j.ejmech.2008.05.029.
- O. Kouatly, P. Eleftheriou, A. Petrou, D. Hadjipavlou-Litina, and A. Geronikaki, Docking assisted design of novel 4-adamantanyl-2-thiazolylimino-5-arylidene-4-thiazolidinones as potent NSAIDs, SAR QSAR Environ. Res. 29 (2018), pp. 83–101. doi:https://doi.org/10.1080/1062936X.2017.1410220.
- C. Tratrat, M. Haroun, E. Tsolaki, A. Petrou, A. Gavalas, and A. Geronikaki, Thiazole-based chalcone derivatives as potential anti-inflammatory agents: Biological evaluation and molecular modelling, Curr. Top. Med. Chem. 21 (2021), pp. 257–268. doi:https://doi.org/10.2174/1568026621999201214232458.
- A. Geronikaki, A. Petrou, V. Kartsev, P. Eleftheriou, R. Boga, B. Bartolo, E. Crespan, G. Franco, and G. Maga, Molecular docking, design, synthesis and biological evaluation of novel 2,3-aryl-thiazolidin-4-ones as potent NNRTIs, SAR QSAR Environ. Res. 30 (2019), pp. 697–714. doi:https://doi.org/10.1080/1062936X.2019.1653364.
- M. Saxena, S. Nandi, and A.K. Saxena, QSAR and molecular docking studies of lethal factor protease inhibitors against Bacillus anthracis, SAR QSAR Environ. Res. 30 (2019), pp. 715–731. doi:https://doi.org/10.1080/1062936X.2019.1658219.
- R. Vinegar, W. Schreiber, and R. Hugo, Biphasic development of carrageenin edema in rats, J. Pharmacol. Exp. Ther. 166 (1969), pp. 96–103.
- P. Theodosis-Nobelos, G. Papagiouvannis, P. Kourounakis, and E. Rekka, Active anti-inflammatory and hypolipidemic derivatives of lorazepam, Molecules 24 (2019), pp. 3277–3285. doi:https://doi.org/10.3390/molecules24183277.
- A. Geronikaki, A. Geronikaki, P. Eleftheriou, D. Hadjipavlou-Litina, D. Filimonov, and V. Poroikov, Computer-aided discovery of potential anti-inflammatory thiazolidinones with dual 5-LOX/COX inhibition, J. Med. Chem. 51 (2008), pp. 1601–1609. doi:https://doi.org/10.1021/jm701496h.
- G. Morris, R. Huey, W. Lindstrom, M. Sanner, R. Belew, D. Goodsell, and A. Olson, Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 16 (2009), pp. 2785–2791. doi:https://doi.org/10.1002/jcc.21256.
- N. Gilbert, J. Gerstmeier, E. Schexnaydre, F. Börner, U. Garscha, D. Neau, O. Werz, and M. Newcomer, Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products, Nat. Chem. Biol. 16 (2020), pp. 783–790. doi:https://doi.org/10.1038/s41589-020-0544-7.
- G. Wolber and T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model. 45 (2005), pp. 160–169. doi:https://doi.org/10.1021/ci049885e.
- C. Tratrat, M. Haroun, A. Paparisva, C. Kamoutsis, A. Petrou, A. Gavalas, P. Eleftheriou, A. Geronikaki, K.N. Venugopala, H. Kochkar, and A.B. Nair, New substituted 5-benzylideno-2-adamantylthiazol [3, 2-b][1, 2, 4] triazol-6 (5h) ones as possible anti-inflammatory agents, Molecules 26 (2021), pp. 659–668. doi:https://doi.org/10.3390/molecules26030659.
- M.-T. Le, T.T. Mai, P.N.H. Huynh, T.-D. Tran, K.-M. Thai, and Q.-T. Nguyen, Structure-based discovery of interleukin-33 inhibitors: A pharmacophore modelling, molecular docking, and molecular dynamics simulation approach, SAR QSAR Environ. Res. 31 (2020), pp. 883–904. doi:https://doi.org/10.1080/1062936X.2020.1837239.
- M. Arora, S. Choudhary, and O. Silakari, In silico guided designing of 4-(1H-benzo[d]imidazol-2-yl)phenol-based mutual-prodrugs of NSAIDs: Synthesis and biological evaluation, SAR QSAR Environ. Res. 31 (2020), pp. 761–784. doi:https://doi.org/10.1080/1062936X.2020.1810117.
- Z. Kalaki and M. Asadollahi-Baboli, Molecular docking-based classification and systematic QSAR analysis of indoles as Pim kinase inhibitors, SAR QSAR Environ. Res. 31 (2020), pp. 399–419. doi:https://doi.org/10.1080/1062936X.2020.1751277.